{
    "atc_code": "L02BB04",
    "ema_number_id": "2639",
    "eu_nas": true,
    "ec_decision_time_days": 3544,
    "ema_number_certainty": "0.7333333333333333",
    "eu_od_pnumber": "__SCRAPER_NOT_FOUND__",
    "ema_procedure_start_initial": "2012-06-26",
    "eu_med_type": "small molecule",
    "ema_reexamination": "False",
    "chmp_opinion_date": "2013-04-25",
    "eu_mah_current": [
        {
            "value": "Astellas Pharma Europe B.V.",
            "date": "2023-01-07"
        }
    ],
    "eu_od_sponsor": [
        {
            "value": "__SCRAPER_NOT_FOUND__",
            "date": "2023-01-07"
        }
    ],
    "eu_aut_date": "2013-06-21",
    "eu_mah_initial": {
        "value": "Astellas Pharma Europe B.V.",
        "date": "2023-01-07"
    },
    "eu_orphan_con_current": [
        {
            "value": "__SCRAPER_NOT_FOUND__",
            "date": "2023-01-07"
        }
    ],
    "eu_od_comp_date": "Date is left blank in source",
    "eu_aut_type_initial": {
        "value": "__SCRAPER_NOT_FOUND__",
        "date": "2023-01-07"
    },
    "ema_number_check": true,
    "eu_prime_initial": {
        "value": "Not available at time of release",
        "date": "2023-01-07"
    },
    "eu_referral": "False",
    "eu_aut_type_current": [
        {
            "value": "standard",
            "date": "2023-01-07"
        }
    ],
    "eu_indication_initial": {
        "value": "xtandi is indicated for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy.\n",
        "date": "2023-01-07"
    },
    "eu_od_initial": {
        "value": "__SCRAPER_NOT_FOUND__",
        "date": "2023-01-07"
    },
    "eu_pnumber": "EU/1/13/846",
    "eu_suspension": "False",
    "eu_od_date": "Date is left blank in source",
    "eu_legal_basis": [
        "article 8.3"
    ],
    "ema_omar_condition": "__SCRAPER_NOT_FOUND__",
    "ema_rapp": "arantxa sancho-lopez",
    "aut_url": "https://ec.europa.eu/health/documents/community-register/2013/20130621126031/dec_126031_en.pdf",
    "omar_url": "404_url_not_found",
    "eu_procedures_todo": [
        {
            "eu_referral": false,
            "eu_suspension": false
        }
    ],
    "smpc_url": "https://ec.europa.eu/health/documents/community-register/2013/20130621126031/anx_126031_en.pdf",
    "ema_corapp": "bengt ljungberg",
    "odwar_url": "404_url_not_found",
    "epar_url": "https://www.ema.europa.eu/documents/assessment-report/xtandi-epar-public-assessment-report_en.pdf",
    "orphan_status": "h",
    "active_substance": "enzalutamide",
    "eu_accel_assess_g": "True",
    "eu_atmp": false,
    "eu_od_number": "__SCRAPER_NOT_FOUND__",
    "eu_aut_status": [
        {
            "value": "ACTIVE",
            "date": "2023-01-07"
        }
    ],
    "ema_od_number": "__SCRAPER_NOT_FOUND__",
    "eu_brand_name_current": [
        {
            "value": "Xtandi",
            "date": "2023-01-07"
        }
    ],
    "assess_time_days_active": "Not found",
    "eu_brand_name_initial": {
        "value": "Xtandi",
        "date": "2023-01-07"
    },
    "eu_od_con": "__SCRAPER_NOT_FOUND__",
    "assess_time_days_cstop": "Not found",
    "ema_number": "EMEA/H/C/2639",
    "assess_time_days_total": 303
}